- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04583098
The Effect of Fecal Microbiota Transplantation on the Decolonization of Multidrug-resistant Organisms
The Effect of Fecal Microbiota Transplantation on the Decolonization of Carbapenem-resistant Enterobacteriaceae or Vancomycin-resistant Enterococci in the Gut
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study is a prospective observational cohort study exploring the decolonization effect of Fecal Microbiota Transplantation (FMT) in patients colonized with Carbapenem-resistant Enterobacteriaceae (CRE) and Vancomycin-resistant Enterococci (VRE).
Patients who have provided written consent for participation in the study will be required to maintain fasting starting from the evening before the procedure, after discontinuing broad-spectrum antibiotics for a minimum of 3-7 days. Subsequently, a bowel preparation will be carried out twice - the evening before and the morning of the procedure. Once the bowel preparation is complete, 1 hour before the procedure, patients will receive loperamide to reduce bowel movements and then proceed to the endoscopy suite.
Fecal microbiota transplantation (FMT) will be carried out with the acquired frozen donor stool, which will be thawed for 2 hours at room temperature following purchase and delivery from a stool bank, under the consent and supervision of the patient or guardian. Frozen stool from carefully screened donors who have passed the rigorous screening of both Stage 1 clinical assessment and Stage 2 laboratory tests (including evaluation for antibiotic resistance organisms) will be supplied from a stool bank of Microbiotix inc. (Hyun Soo Seo, et al. Ann Lab Med 2021;41:424-428).
The FMT procedure will be conducted in collaboration with the research team in the Division of Gastroenterology. During the procedure, no tissue biopsy or excessive endoscope insertion will be performed. The FMT involves the simple infusion of thawed donor stool into the terminal ileum under colonoscopy, which takes approximately 5-10 minutes. The procedure carries minimal risk of bleeding, perforation, or aspiration. In most cases, it will be performed under sedation with colonoscopy. If smooth insertion of the colonoscope or proper visualization of the colon is hindered, or if colonic preparation is not successful, Esophagogastroduodenoscopy (EGD) will be performed with sedation, and thawed donor stool will be infused into the third portion of the duodenum. This procedure also poses minimal risk of regurgitation or aspiration due to its anatomical and physiological characteristics. After the procedure, the lower extremities will be elevated by about 30 degrees to prevent the transplanted stool from exiting. A one-day fasting period will be maintained after the procedure to facilitate successful engraftment of the transplanted stool, followed by the gradual resumption of a regular diet. Following FMT, repeated rectal swab cultures will be conducted to confirm three consecutive negative results for CP-CRE or VRE at 3-7 day intervals.
In cases where encapsulated fecal material is used for FMT, it will be ingested along with high-acid cranberry or orange juice. The capsules are specially designed to dissolve in low-acidic environments, allowing them to reach the terminal ileum for safe administration without the need for bowel preparation. On the first day, 15 capsules will be consumed, followed by another 15 capsules on the second day, for a total of 30 capsules. Subsequently, repeated rectal swab tests will be conducted to confirm three consecutive negative results for CP-CRE or VRE at 3-day intervals.
According to patient random allocation, fecal samples and clinical metadata will be periodically collected (prior to FMT, 1 month, 3 months, 6 months, and 12 months after FMT) from both recipients and donors. These collected samples will undergo full-length 16S rRNA sequencing and shotgun metagenomic sequencing to comprehensively analyze the gut microbiome. Through this analysis, the aim is to elucidate the intestinal microorganisms associated with decolonization outcomes and mechanisms.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Seung Soon Lee, MD
- Phone Number: +82-33-240-5599
- Email: hushh93@gmail.com
Study Contact Backup
- Name: Ki Tae Suk, MD, PhD
- Phone Number: +82332405826
- Email: ktsuk@hallym.or.kr
Study Locations
-
-
Gangwon-do
-
Chuncheon, Gangwon-do, Korea, Republic of, 24253
- Recruiting
- Chuncheon Sacred Heart Hospital
-
Contact:
- Seung Soon Lee, MD
- Phone Number: +82-33-240-5599
- Email: hushh93@gmail.com
-
Contact:
- Ki Tae Suk, MD, PhD
- Phone Number: +82-33-240-5826
- Email: ktsuk@hallym.or.kr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients over 19 years-old with carbapenem-resistant Enterobacteriaceae(CRE) or vancomycin-resistant Enterococci(VRE) rectal colonization
- Patients who have received written informed consent for fecal microbiota transplantation and collection of stool samples
Exclusion Criteria:
- Patients who have not completed acute-phase treatment, including antibiotic treatment
- If patients are pregnant, may be pregnant, or are lactating
- Patients who have not received written informed consent for the study enrollment
- Patients who are judged to be unhelpful to participate in the study according to the researcher's judgment
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
carbapenem-resistant Enterobacteriaceae
FMT using frozen or capsulized stool
|
frozen or capsulized stool from donors who had already finished recommended blood & stool screening for stool donors
|
vancomycin-resistant Enterococci
FMT using frozen or capsulized stool
|
frozen or capsulized stool from donors who had already finished recommended blood & stool screening for stool donors
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
successful decolonization of carbapenem-resistant Enterobacteriaceae or vancomycin-resistant Enterococci in the gut within 3 months after fecal microbiota transplantation
Time Frame: within 3 months
|
Successful decolonization of carbapenem-resistant Enterobacteriaceae or vancomycin-resistant Enterococci was defined as three consecutive, carbapenem-resistant Enterobacteriaceae or vancomycin-resistant Enterococci-negative surveillance rectal swab cultures repeated with a 3-day interval within 3 months after fecal microbiota transplantation
|
within 3 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Seung Soon Lee, MD, Chuncheon Sacred Heart Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020-08-006
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carbapenem-Resistant Enterobacteriaceae Infection
-
The Methodist Hospital Research InstituteM.D. Anderson Cancer Center; National Institute of Allergy and Infectious Diseases... and other collaboratorsRecruitingAntibiotic Resistant Infection | Clostridium Difficile | Antimicrobial Drug Resistance | Carbapenem-Resistant Enterobacteriaceae Infection | Vancomycin Resistant Enterococci Infection | Vancomycin-Resistant Enterococcal Infection | Carbapenem Resistant Bacterial Infection | Extended Spectrum Beta-Lactamase...United States
-
Chuncheon Sacred Heart HospitalSeverance Hospital; National Institute of Health, KoreaRecruitingCarbapenem-Resistant Enterobacteriaceae | Vancomycin (Glycopeptide) Resistant Enterococcus (VRE)Korea, Republic of
-
University of BolognaHospital General Universitario Gregorio Marañon; IRCCS ISMETT Palermo; ASST-Sette... and other collaboratorsNot yet recruitingLiver Transplantation | Carbapenem-Resistant Enterobacteriaceae ColonizationSpain, Brazil, Italy
-
Kaleido BiosciencesTerminatedVancomycin-Resistant Enterococcus, Extended-Spectrum Beta Lactamase-Producing Enterobacteriaceae, or Carbapenem-Resistant Enterobacteriaceae Colonized SubjectsUnited States
-
Hanoi University of Public HealthKarolinska Institutet; University of Copenhagen; National Children's Hospital... and other collaboratorsRecruitingAntibiotic Resistant Infection | Carbapenem-Resistant Enterobacteriaceae InfectionVietnam
-
Hospital Moinhos de VentoTerminatedSepsis | Gram-Negative Bacterial Infections | Bacteremia | Severe Infection | Bloodstream Infection | Acinetobacter Infections | Pseudomonas Aeruginosa | Human | Carbapenem-Resistant Enterobacteriaceae Infection | Carbapenem Resistant Bacterial InfectionBrazil
-
Sir Run Run Shaw HospitalRecruitingHematological Diseases | Carbapenem-resistant Enterobacteriaceae | Carbapenem-resistant Pseudomonas Aeruginosa | Carbapenem-resistant Acinetobacter BaumanniiChina
-
Tan Tock Seng HospitalSingapore Clinical Research InstituteNot yet recruitingCarbapenem-Resistant Enterobacteriaceae Infection
-
Phramongkutklao College of Medicine and HospitalSilpakorn UniversityRecruitingCarbapenem-resistant EnterobacteriaceaeThailand
-
Wake Forest University Health SciencesMerck Sharp & Dohme LLCWithdrawnGram-Negative Bacterial Infections | Antibiotic Resistant Infection | Carbapenem-Resistant Enterobacteriaceae Infection | KPCUnited States
Clinical Trials on fecal microbiota transplantation
-
Madhusudan (Madhu) Grover, MBBSRecruiting
-
Medical University of GrazBristol-Myers SquibbTerminatedMalignant Melanoma Stage III | Malignant Melanoma Stage IV | Fecal Microbiota TransplantationAustria
-
Children's Mercy Hospital Kansas CityUniversity of Pittsburgh; Stanford UniversityCompletedUlcerative Colitis (UC) | Inflammatory Bowel Diseases (IBD) | Crohn's Disease (CD)United States
-
The Second Hospital of Nanjing Medical UniversitySIR RUN RUN hospital of Nanjing Medical UniversityNot yet recruitingAutism Spectrum Disorder
-
The Second Hospital of Nanjing Medical UniversityRecruitingCancer | Intestinal ComplicationsChina
-
The First Affiliated Hospital of Nanchang UniversityCompletedAcute Pancreatitis | Intestinal Bacteria Flora Disturbance | Fecal Microbiota Transplantation | Intestinal DysfunctionChina
-
The Second Hospital of Nanjing Medical UniversityWithdrawnCOVID-19 Complicated With Refractory Intestinal InfectionsChina
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingAllogeneic Hematopoietic Stem CellUnited States
-
The University of Texas Health Science Center,...TerminatedRecurrent C. Difficile InfectionUnited States
-
Chinese University of Hong KongActive, not recruitingIrritable Bowel Syndrome | Fecal Microbiota TransplantationHong Kong